Wall Street resets targets on Afya as Brazil risk hits Nasdaq
Afya Limited shares fell 3.33% to $10.15 on November 6, 2026, as Wall Street analysts cut price targets following Brazil's post-election market volatility.
American retail investors holding shares of medical education provider Afya Limited saw their portfolios dip on November 6, 2026, as Wall Street analysts adjusted their expectations for one of the few Brazilian companies listed directly on a U.S. exchange. The stock fell 3.33% to close at $10.15, hovering near the lower end of its 52-week trading range of $9.66 to $16.16.
The downward pressure follows a wave of political risk in Brazil that has triggered a broader selloff in South American assets. Following the country's recent presidential runoff, the benchmark Bovespa index faced sharp declines, and the Brazilian real weakened. The shifting macroeconomic landscape prompted major financial institutions to revise their outlooks for Brazilian equities. On November 5, 2026, Morgan Stanley upgraded Afya to equalweight from underweight but lowered its price target to $12.60 from $15.00, citing caution over student enrollment trends and structural market shifts. This followed moves by Citigroup, which upgraded the stock to buy but slashed its price target to $12.00 from $16.00, pointing to a higher cost of capital in Brazil.
Unlike most Brazilian corporations that trade in New York via American Depositary Receipts (ADRs), Afya is a Cayman Islands-incorporated entity with a primary listing on the Nasdaq. Founded in 1999 and headquartered in Belo Horizonte, Brazil, the company is the country's largest medical education group by number of medical school seats. This corporate structure means retail investors buy the common stock directly, avoiding the specialized custody fees often associated with ADRs.
Beyond macroeconomic headwinds, investors are closely monitoring a pending all-stock merger with Brazilian education giant Yduqs Participações, which was formally agreed upon on September 23, 2026. Under the terms of the transaction, Afya would merge into Yduqs and cease to exist as a separate legal entity. Shareholders of Afya would receive newly issued Yduqs common shares. Crucially for U.S. retail accounts, the combined company plans to list exclusively on Brazil's B3 exchange, meaning Afya would eventually delist from the Nasdaq and tie investor returns directly to the Brazilian real.
Afya is scheduled to report its third-quarter 2026 financial results after the market closes on Thursday, November 12, 2026. Wall Street analysts expect the company to post earnings of $0.3791 per share on revenue of $190.41 million. Whether the upcoming earnings report can offset the mounting political discount hanging over Brazilian equities remains the key question for shareholders ahead of the proposed merger.
In your brokerage app
Afya Limited is listed in New York on the Nasdaq under the ticker AFYA. Because it is a primary U.S. listing rather than an ADR, retail investors can trade its common shares directly through standard brokerage accounts. The stock is also held by specialized exchange-traded funds, including the VanEck Brazil Small-Cap ETF.
